Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma – a case report and review of the literature

Open access
Nuytemans, Laure, Sys, Gwen, Creytens, David, Lapeire, Lore · 2021 · Acta Clinica Belgica

Abstract

Background: The prognosis and treatment of metastatic osteosarcoma have not changed in the last decades and the responses to chemotherapy in this setting are disappointing. In the past years, immunotherapy has found its place in the treatment of different tumor types. Its role in the treatment of sarcomas, and in particular osteosarcoma, is less clear. Next-generation sequencing (NGS) can help identify patients who could benefit from immunotherapy.Methods: Single case study and review of the literatureCase summary and intervention: We discuss a case of a 26-year-old man with a metastatic osteosarcoma not responsive to several lines of standard chemotherapy. NGS-analysis of resected tumor tissue revealed amplification of PD-L1 and PD-L2, which is associated in literature with response to anti-PD-1/PD-L1 blockade in other tumor types and in osteosarcoma mouse models. Treatment of our patient with the combination of an anti-PD-1 antibody (Nivolumab) and an anti-CTLA4 antibody (Ipilimumab) showed a stabilization of life-threatening retrocardiac tumoral masses that had previous significantly progressed despite radiotherapy, while one bone lesion in the right os ilium was growing and needed treatment with concomitant radiotherapy.Conclusion: To our knowledge, this is the first case report of a metastasized osteosarcoma patient with no further standard treatment options being treated with dual checkpoint inhibition. A complete stabilization of life-threatening retrocardiac lesions could be achieved and with the addition of radiotherapy to a growing bone lesion, the patient is still doing well. NGS-analysis can help identify druggable targets in patients with rare tumors with limited treatment options.Abbreviations: PD-L1: Programmed death-ligand 1; anti-PD-L1: anti-programmed death-ligand 1; PD-1: programmed cell death protein 1; anti-PD-1: anti-programmed cell death protein 1; anti-CTLA4: anti-cytotoxic T-lymphocyte-associated protein 4; AUC: area under the curve; NGS: next-generation sequencing; Gy: Gray; CT scan: computed tomography scan; RCC: renal cell carcinoma; IHC: immunohistochemistry; TMB: tumor mutational burden; NSCLC: Non-small cell lung cancer.

Overview

Integrity signals

Registry

Crossref · 10.1080/17843286.2019.1683129

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. Geller DS, 2010, Clin Adv Hematol Oncol, 8, 705

Cited by

See all 16

Metadata

Authors
Nuytemans, L., Sys, G., Creytens, D., & Lapeire, L.
Affiliations
Ghent University Hospital (BE)
Corresponding author
Nuytemans, Laure
Venue
Acta Clinica Belgica
Published
2019-10-21
Volume
76
Issue
2
Pages
162-167
ISSN
  • 1784-3286 (ISSN-L)
  • 2295-3337
OpenAlex
W2982082744
Cited by
16
References
24
Citations by year
2025: 4 · 2024: 2 · 2023: 5 · 2022: 2 · 2021: 2 · 2020: 1
FWCI
0.93
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Acta Clinica Belgica (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (publishedVersion, other-oa)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Keywords
metastatic osteosarcoma, PD-L2, anti-PD-1, nivolumab, anti-CTLA-4 antibody, ipilimumab, immunotherapy, next-generation sequencing, tumor mutational burden, radiotherapy
MeSH terms
Adult, Animals, Carcinoma, Non-Small-Cell Lung, Humans, Kidney Neoplasms, Lung Neoplasms, Male, Osteosarcoma, Mice, High-Throughput Nucleotide Sequencing, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma – a case report and review of the literature. https://app.cochat.ai/papers/10.1080/17843286.2019.1683129
The paper
Nuytemans, L., Sys, G., Creytens, D., & Lapeire, L. (2021). NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma – a case report and review of the literature. Acta Clinica Belgica. https://doi.org/10.1080/17843286.2019.1683129

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.